American Century Companies
NGM

American Century Companies’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

American Century Companies’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,738
Closed -$40.8K – 2905
2023
Q2 		$40.8K Buy
+15,738
New +$56.1K ﹤0.01% 2774

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

American Century Companies's NGM Position: Q3 2023 in Review

American Century Companies sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q3 2023, closing a stake of 15,738 shares — an estimated $40.8K sold.

American Century Companies first reported a position in NGM in Q2 2023 and held it in 1 quarter. The position peaked at $40.8K in Q2 2023. 94 funds tracked by Wall St. Rank hold NGM as of Q3 2023.

  • American Century Companies reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • American Century Companies sold 15,738 NGM Biopharmaceuticals, Inc. Common Stock shares in Q3 2023, an estimated $40.8K.
  • American Century Companies first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2023 and held it in 1 quarter.
  • American Century Companies's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $40.8K in Q2 2023.
  • 94 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q3 2023.

Based on American Century Companies's 13F filing for Q3 2023, filed 13 Nov 2023.